Skip to main
AMPH

Amphastar Pharma (AMPH) Stock Forecast & Price Target

Amphastar Pharma (AMPH) Analyst Ratings

Based on 6 analyst ratings
Hold
Strong Buy 17%
Buy 17%
Hold 67%
Sell 0%
Strong Sell 0%

Bulls say

Amphastar Pharmaceuticals Inc. has demonstrated solid financial performance with a 10% quarter-over-quarter increase and a 5% year-over-year growth in top-line revenue, reaching $191.8 million in 3Q25, surpassing market expectations. The company reports promising sales growth for its product Baqsimi, which increased approximately 20% quarter-over-quarter and is expected to experience high-single digit unit growth in 2025, supported by collaborations and seasonal demand. Additionally, the firm anticipates a return to double-digit growth by 2026, alongside upcoming approvals and launches of new products that could further enhance revenue streams.

Bears say

Amphastar Pharmaceuticals, Inc. faces significant headwinds as competition increases for its key products, leading to substantial downward adjustments in revenue expectations. The company’s iron sucrose sales are projected to significantly underperform, with estimates revised from $60 million annually to approximately $20 million due to heightened competition and supply challenges. Additionally, glucagon sales are expected to decline below $70 million by 2026 as the market transitions from a sole player to a more competitive environment, further dampening prospects for top-line growth in the coming years.

Amphastar Pharma (AMPH) has been analyzed by 6 analysts, with a consensus rating of Hold. 17% of analysts recommend a Strong Buy, 17% recommend Buy, 67% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Amphastar Pharma and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Amphastar Pharma (AMPH) Forecast

Analysts have given Amphastar Pharma (AMPH) a Hold based on their latest research and market trends.

According to 6 analysts, Amphastar Pharma (AMPH) has a Hold consensus rating as of Mar 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $29.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $29.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Amphastar Pharma (AMPH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.